Αυγ262015Βιβλιογραφικά δεδομέναΓια να δείτε το άρθρο πιέστε εδώ Κατηγορία Βιβλιογραφικά δεδομένα26 Αυγούστου 2015 Μοιραστείτε το! Share on FacebookShare on Facebook Share on XShare on X Share on LinkedInShare on LinkedIn Share on WhatsAppShare on WhatsApp Post navigationΠροηγούμενοPrevious post:Toward a More Complete Understanding of the Association Between a Hepatitis C Sustained Viral Response and Cause-Specific OutcomesΕπόμενοNext post:The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infectionΣχετικά ΆρθραThe Rise of Transplant Oncology in Primary Liver Cancer and Metastatic Disease10 Μαρτίου 2026Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program3 Μαρτίου 2026Early Prognostic Factors for Reduced Survival in Autoimmune Hepatitis: A Systematic Review With Meta-Analysis27 Φεβρουαρίου 2026Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation18 Φεβρουαρίου 2026Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis2 Φεβρουαρίου 2026Autoimmune liver diseases in Latin America: Current landscape and challenge29 Ιανουαρίου 2026
Safety and efficacy of REP 2139-Mg in patients with HDV-related advanced liver disease in an international compassionate access program3 Μαρτίου 2026
Early Prognostic Factors for Reduced Survival in Autoimmune Hepatitis: A Systematic Review With Meta-Analysis27 Φεβρουαρίου 2026
Clinical outcomes in MetALD compared with ALD in patients referred for liver transplant evaluation18 Φεβρουαρίου 2026
Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis2 Φεβρουαρίου 2026
